Indication
Beovu is indicated in adults for the treatment of neovascular (wet) age-related macular degeneration (AMD).
Loading your page…
Loading your page…
Wet Macular Degeneration
Marketing Authorisation Holder: Novartis Europharm Limited
EMA Authorisation: 13/02/2020
INN: brolucizumab
AI Drug & Interaction Analysis
Free account required
Ask Osler about Beovu: drug interactions and guideline evidence, with every claim numbered to its source. For reference and learning, not treatment advice.
Medical disclaimer: This information is intended for qualified healthcare professionals. Always verify with the official EMA Summary of Product Characteristics (SmPC) before clinical use.